The Swiss pharmaceutical company learned that some of its employees had manipulated data in the Zolgensma application in March, but instead of telling the Food and Drug Administration immediately, Novartis conducted its own investigation and submitted the results to the FDA in late June, about one month after Zolgensma was approved by the FDA.
In a letter to Novartis CEO Vas Narasiman, Mr. Grassley asked the company to provide all records about the issue, including results of its internal inquiry and the number of employees terminated as a result of the error.
Mr. Narasiman was given a deadline of Aug. 23 to respond to the letter.
More articles on pharmacy:
CMS to cover CAR-T therapy nationwide
Colombia fines Pfizer $25K for drug price inflation
Jefferson Healthcare opens retail specialty pharmacy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
